Souhaitez-vous accéder aux communiqués récents ?

Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Biotalys announces that it will publish its annual report and financial results for the full year of 2025 on Wednesday, 29 April 2026 at 07:00 CEST.

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results...

First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients...

Xunxi brings RMB 340 million in audited 2025 revenue, 200+ institutional clients, and a 2 million-member digital commerce platform.

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

Dubai, UAE, March 23, 2026 (GLOBE NEWSWIRE) -- New crypto Pepeto team announces that the project advancement is nearing launch, and it just crossed $8.3 million because experienced crypto investors...

CALGARY, Alberta, March 23, 2026 (GLOBE NEWSWIRE) -- CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) ("CEMATRIX" or the "Company"), a specialty construction contractor that produces cellular...

Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the...